Leerink Partnrs Estimates Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities researchers at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.89) for the year. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA's Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $0.16 EPS, FY2028 earnings at $1.29 EPS and FY2029 earnings at $1.82 EPS.

ATYR has been the topic of several other reports. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Leerink Partners initiated coverage on Atyr PHARMA in a report on Tuesday. They set an "outperform" rating and a $16.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Trading Down 2.5 %

Shares of NASDAQ ATYR traded down $0.11 during midday trading on Thursday, hitting $4.32. The stock had a trading volume of 1,767,908 shares, compared to its average volume of 987,059. The company has a market capitalization of $362.62 million, a price-to-earnings ratio of -4.60 and a beta of 1.10. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $3.61 and a 200 day moving average price of $2.87.

Institutional Investors Weigh In On Atyr PHARMA

Hedge funds and other institutional investors have recently bought and sold shares of the business. Group One Trading LLC purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $26,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $37,000. Raymond James Financial Inc. purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $39,000. Finally, XTX Topco Ltd purchased a new stake in Atyr PHARMA during the 4th quarter worth approximately $40,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.